Inovio Biomedical is collaborating with RMR to license a technology for delivering gene-based therapeutics into skin -- a method called "electroporation" -- for a number of applications including an anthrax vaccine, the company said.

Inovio announced May 15 it had acquired rights to several patent families relating to the use of electroporation technology under a license with Sphergen SARL. The technology covers various skin electroporation methods, including a needle-less design using a flexible material that conforms to the skin contour.